Champions Oncology (CSBR) Expected to Announce Quarterly Earnings on Thursday

Champions Oncology (NASDAQ:CSBR) is anticipated to issue its Q1 2027 results after the market closes on Thursday, September 10th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $15.0450 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2027 earning results page for the latest details on the call scheduled for Thursday, September 10, 2026 at 4:30 PM ET.

Champions Oncology (NASDAQ:CSBR) last released its quarterly earnings data on Monday, July 27th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. The firm had revenue of $13.84 million for the quarter, compared to the consensus estimate of $12.89 million. Champions Oncology had a negative return on equity of 27.48% and a negative net margin of 1.87%.

Champions Oncology Price Performance

CSBR stock opened at $5.22 on Tuesday. The firm has a 50 day moving average of $5.49 and a two-hundred day moving average of $5.83. Champions Oncology has a 12 month low of $4.83 and a 12 month high of $8.74. The company has a market capitalization of $72.66 million, a price-to-earnings ratio of -65.25 and a beta of 0.40.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Trading of Champions Oncology

Institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in Champions Oncology in the 2nd quarter valued at $103,000. Essex Investment Management Co. LLC acquired a new position in Champions Oncology during the 4th quarter worth $126,000. Jane Street Group LLC bought a new stake in Champions Oncology during the first quarter valued at about $200,000. Goldman Sachs Group Inc. bought a new stake in Champions Oncology during the first quarter valued at about $201,000. Finally, Acadian Asset Management LLC grew its position in shares of Champions Oncology by 28.7% in the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock valued at $341,000 after purchasing an additional 8,814 shares during the last quarter. 41.30% of the stock is currently owned by institutional investors and hedge funds.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.